19-Apr-2024
No headlines found.
Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
Business Wire (Thu, 11-Apr 8:30 AM ET)
Baxter to Host First-Quarter 2024 Financial Results Conference Call for Investors
Business Wire (Wed, 10-Apr 4:15 PM ET)
Business Wire (Mon, 1-Apr 7:15 AM ET)
Globe Newswire (Thu, 28-Mar 1:07 PM ET)
Baxter to Host Annual Meeting of Stockholders in Virtual Format
Business Wire (Wed, 27-Mar 9:00 AM ET)
Baxter to Present at Raymond James 45th Annual Institutional Investors Conference
Business Wire (Thu, 29-Feb 4:15 PM ET)
Globe Newswire (Wed, 21-Feb 4:00 PM ET)
Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients
Globe Newswire (Thu, 15-Feb 7:42 AM ET)
Baxter Declares Quarterly Dividend
Business Wire (Mon, 12-Feb 6:15 PM ET)
Baxter Reports Fourth-Quarter and Full-Year 2023 Results
Business Wire (Thu, 8-Feb 7:15 AM ET)
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.
Baxter Intl trades on the NYSE stock market under the symbol BAX.
As of April 19, 2024, BAX stock price declined to $39.47 with 2,664,993 million shares trading.
BAX has a beta of 1.09, meaning it tends to be more sensitive to market movements. BAX has a correlation of 0.18 to the broad based SPY ETF.
BAX has a market cap of $20.10 billion. This is considered a Large Cap stock.
Last quarter Baxter Intl reported $4 billion in Revenue and $.88 earnings per share. This beat revenue expectation by $85 million and exceeded earnings estimates by $.02.
In the last 3 years, BAX stock traded as high as $89.70 and as low as $31.01.
The top ETF exchange traded funds that BAX belongs to (by Net Assets): VTI, VOO, VO, SPY, IVV.
BAX has underperformed the market in the last year with a price return of -5.1% while the SPY ETF gained +21.2%. BAX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +2.4% and -7.4%, respectively, while the SPY returned +4.3% and -3.5%, respectively.
BAX support price is $39.05 and resistance is $40.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BAX stock will trade within this expected range on the day.